{"success":true,"data":{"pressRelease":{"id":"26138","rtpr_id":"nACS3Wyypa","ticker":"CMPX","exchange":"NASDAQ","all_tickers":["CMPX"],"title":"Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Investors to Connect","author":"ACCESSWIRE","published_at":"2026-05-07T15:00:07.890Z","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 7,\n2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on\nbehalf of purchasers of Compass Therapeutics, Inc. (\"Compass\" or \"the\nCompany\") (NASDAQ:CMPX). Investors who purchased Compass securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/CMPX.\n(https://bgandg.com/CMPX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=CMPX)\n(https://app.accessnewswire.com/imagelibrary/221ed34a-95d4-4d75-9c62-55867176d3a1/image.png)\nCompass Investigation Details\n\nOn April 27, 2026, Compass issued a press release announcing results from a\nphase 2/3 study evaluating its drug tovecimig as a biliary tract cancer\ntreatment. Although the press release emphasized that the study \"met the key\nsecondary endpoint of [progression-free survival] and showed additional\ncompelling results\", the study also missed another key secondary endpoint,\noverall survival. Following this news, Compass's stock price dropped $3.24 per\nshare, or 64.41%, to close at $1.79 on April 27, 2026.\n\nWhat's Next for Compass Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nCompass securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/CMPX\n(https://bgandg.com/CMPX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=CMPX).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Compass Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Compass Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-compass-ther-1162496)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved.","article_body_html":"","raw_payload":{"data":{"id":"nACS3Wyypa","title":"Bronstein, Gewirtz & Grossman, LLC Is Investigating Compass Therapeutics, Inc. (CMPX) And Encourages Investors to Connect","author":"ACCESSWIRE","ticker":"CMPX","created":"2026-05-07T15:00:07.890Z","tickers":["CMPX"],"exchange":"NASDAQ","article_body":"NEW YORK CITY, NY / ACCESS Newswire (https://www.accessnewswire.com/) / May 7,\n2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on\nbehalf of purchasers of Compass Therapeutics, Inc. (\"Compass\" or \"the\nCompany\") (NASDAQ:CMPX). Investors who purchased Compass securities are\nencouraged to obtain additional information and assist the investigation by\nvisiting the firm's site: bgandg.com/CMPX.\n(https://bgandg.com/CMPX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=CMPX)\n(https://app.accessnewswire.com/imagelibrary/221ed34a-95d4-4d75-9c62-55867176d3a1/image.png)\nCompass Investigation Details\n\nOn April 27, 2026, Compass issued a press release announcing results from a\nphase 2/3 study evaluating its drug tovecimig as a biliary tract cancer\ntreatment. Although the press release emphasized that the study \"met the key\nsecondary endpoint of [progression-free survival] and showed additional\ncompelling results\", the study also missed another key secondary endpoint,\noverall survival. Following this news, Compass's stock price dropped $3.24 per\nshare, or 64.41%, to close at $1.79 on April 27, 2026.\n\nWhat's Next for Compass Investors?\n\nIf you are aware of any facts relating to this investigation or purchased\nCompass securities, you can assist this investigation by visiting the firm's\nsite: bgandg.com/CMPX\n(https://bgandg.com/CMPX/?utm_source=accesswire&utm_medium=pressrelease&utm_campaign=CMPX).\nYou can also contact Peretz Bronstein or his client relations manager, Nathan\nMiller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911 (tel:+9175900911)\n\nNo Cost to Compass Investors\n\nWe, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions\non a contingency fee basis. That means we will ask the court to reimburse us\nfor out-of-pocket expenses and attorneys' fees, usually a percentage of the\ntotal recovery, only if we are successful.\n\nWhy Bronstein, Gewirtz & Grossman, LLC for Compass Securities Investigation?\n\nBronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that\nrepresents investors in securities fraud class actions and shareholder\nderivative suits. Our firm has recovered hundreds of millions of dollars for\ninvestors nationwide.\n\n\"Our practice centers on restoring investor capital and ensuring corporate\naccountability, which serves to uphold the essential integrity of the\nmarketplace,\" said Peretz Bronstein\n(https://www.linkedin.com/in/peretz-bronstein-65a1b411), Founding Partner of\nBronstein, Gewirtz & Grossman, LLC.\n\nFollow us for updates on LinkedIn\n(https://www.linkedin.com/company/bronstein-gewirtz-&-grossman-llc/), X\n(https://x.com/bgandg_law), Facebook (https://www.facebook.com/BGandG/), or\nInstagram (https://www.instagram.com/bg_and_g/).\n\nContact Info\n\nPeretz Bronstein, Esq. or Nathan Miller\nBronstein, Gewirtz & Grossman, LLC\n917-590-0911 (tel:+9175900911) | info@bgandg.com\n\nAttorney advertising.\n\nPrior results do not guarantee similar outcomes.\n\nSOURCE: Bronstein, Gewirtz & Grossman, LLC\nView the original press release\n(https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-compass-ther-1162496)\non ACCESS Newswire\n\n\nCopyright 2026 ACCESS Newswire. All Rights Reserved."},"type":"article","timestamp":"2026-05-07T15:00:07.9472971Z","server_sent_at_ms":1778166007947},"received_at":"2026-05-07T15:00:08.009Z","source_url":"https://www.accessnewswire.com/newsroom/en/business-and-professional-services/bronstein-gewirtz-and-grossman-llc-is-investigating-compass-ther-1162496"},"analysis":null,"durationMs":null,"modelName":null}}